These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 204304)

  • 1. Inhibition of 15-hydroxyprostaglandin dehydrogenase by papaverine.
    Iijima Y; Ueno T; Sasagawa K; Yamazaki M
    Biochem Biophys Res Commun; 1978 Feb; 80(3):484-9. PubMed ID: 204304
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of 15-hydroxyprostaglandin dehydrogenase by antiallergic agents.
    Iijima Y; Kawakita N; Yamazaki M
    Biochem Biophys Res Commun; 1980 Apr; 93(3):912-8. PubMed ID: 6104488
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of adenosine-3',5'-cyclic monophosphate phosphodiesterase by potential antiallergic compounds.
    Tateson JE; Trist DG
    Life Sci; 1976 Jan; 18(2):153-61. PubMed ID: 56695
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of cyclic AMP phosphodiesterase by 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-[2-(N-benzyl-N-methylamino)] ethyl ester 5-methyl ester hydrochloride (YC-93), a potent vasodilator.
    Sakamoto N; Terai M; Takenaka T; Maeno H
    Biochem Pharmacol; 1978; 27(8):1269-74. PubMed ID: 81059
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of 15-hydroxyprostaglandin dehydrogenase by 9,11-deoxyprostaglandins in vitro and in vivo.
    Yamazaki M; Ohuchi K; Sasaki M; Sakai K
    Mol Pharmacol; 1981 May; 19(3):456-62. PubMed ID: 7266469
    [No Abstract]   [Full Text] [Related]  

  • 6. Interaction of four methylxanthine compounds and norepinephrine on cardiac phosphorylase activation and cardiac contractility.
    McNeill JH; Brenner MJ; Muschek LD
    Recent Adv Stud Cardiac Struct Metab; 1973; 3():261-73. PubMed ID: 4377599
    [No Abstract]   [Full Text] [Related]  

  • 7. Antispasmodic action of 1-diethylaminoethyl-3-(p-methoxybenzyl)-2-quinoxalone (P 201-1) and its inhibitory effect on cyclic 3',5'-nucleotide phosphodiesterase (PDE) activity.
    Hayashi S; Ozawa H
    Chem Pharm Bull (Tokyo); 1975 Apr; 23(4):810-6. PubMed ID: 171085
    [No Abstract]   [Full Text] [Related]  

  • 8. A 15-hydroxyprostaglandin dehydrogenase specific for prostaglandin A in rabbit kidney.
    Oien HG; Ham EA; Zanetti ME; Ulm EH; Kuehl FA
    Proc Natl Acad Sci U S A; 1976 Apr; 73(4):1107-11. PubMed ID: 4794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silymarin: potent inhibitor of cyclic AMP phosphodiesterase.
    Koch HP; Bachner J; Löffler E
    Methods Find Exp Clin Pharmacol; 1985 Aug; 7(8):409-13. PubMed ID: 3001454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of calmodulin dependent c-AMP-phosphodiesterase by moxaverine and papaverine.
    Mannhold R
    Arzneimittelforschung; 1988 Dec; 38(12):1806-8. PubMed ID: 2854468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors.
    Ashida S; Sakuma K
    Adv Second Messenger Phosphoprotein Res; 1992; 25():229-39. PubMed ID: 1313259
    [No Abstract]   [Full Text] [Related]  

  • 12. [The effect of the benzimidazole derivative AR-L 115 BS on the activities of myocardial adenylate cyclase and phosphodiesterase preparations (author's transl)].
    Schuhmacher P; Greeff K; Noack E
    Arzneimittelforschung; 1982; 32(1):80-2. PubMed ID: 6277343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The action mechanism of trapidil (Rocornal)].
    Lampe D; Mai I; Busse E
    Pharmazie; 1975 Dec; 30(12):807-8. PubMed ID: 176671
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of cyclic AMP phosphodiesterase inhibitors on cardiac sarcolemmal 5'-nucleotidase.
    Heyliger CE; Panagia V; Dhalla NS
    J Pharmacol Exp Ther; 1981 May; 217(2):489-93. PubMed ID: 6262487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue and species specificity of cardiac cAMP-phosphodiesterase inhibitors.
    Pang DC
    Adv Second Messenger Phosphoprotein Res; 1992; 25():307-20. PubMed ID: 1313264
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of papaverine analogues on 3', 5'-adenosine monophosphate phosphodiesterase activity in rat brain.
    Stancheva S; Uzunov P; Stoytchev T
    Acta Physiol Pharmacol Bulg; 1980; 6(1):41-7. PubMed ID: 6250318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of pulmonary NAD+-dependent 15-hydroxyprostaglandin dehydrogenase by acrolein.
    Liu Y; Tai HH
    Biochem Pharmacol; 1985 Dec; 34(24):4275-8. PubMed ID: 4074386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of chlorphenesin and divalent metal ions with phosphodiesterase.
    Edelson J; McMullen JP
    Arch Int Pharmacodyn Ther; 1976 Sep; 223(1):24-33. PubMed ID: 187130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological inhibition of calmodulin-sensitive phosphodiesterases.
    Ilien B; Ruckstuhl M; Landry Y
    J Pharmacol; 1982; 13(2):307-16. PubMed ID: 6285085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic evidence of a distinct regulatory site on 15-hydroxyprostaglandin dehydrogenase.
    Tai HH; Hollander CS
    Adv Prostaglandin Thromboxane Res; 1976; 1():171-5. PubMed ID: 187035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.